Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes
Trial details
- Registry ID
- NCT07392125
- Drugs studied
- Behavioral Support, Cytisinicline
TrialRedline tracks 6 clinical trials sponsored by Achieve Life Sciences: 5 Phase 3, 1 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E CigarettesNCT07392125 | Behavioral Support, Cytisinicline | Not yet recruiting | 2026-11-15Estimated |
| Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette SmokersNCT06435221 | Cytisinicline | Completed | 2025-09-29Actual |
| A Second Study of Cytisinicline for Smoking Cessation in Adult SmokersNCT05206370 | Behavioral support, Cytisinicline | Completed | 2023-03-21Actual |
| A Study of Cytisinicline for Smoking Cessation in Adult SmokersNCT04576949 | Behavioral support, Cytisinicline | Completed | 2021-12-23Actual |
| A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung CancerNCT01630733 | Custirsen, Docetaxel | Completed | 2016-11-17Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of Cytisinicline for Vaping Cessation in Adult SmokersNCT05431387 | Behavioral support, cytisinicline | Completed | 2023-02-28Actual |
Names as written in the registry records.
NCT01630733 · Achieve Life Sciences
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Overall Survival. After: Measure: Overall Survival: All Randomized Population Measure: Overall Survival: Stratified by Histology - Squamous vs. Non-Squamous.
Before: Estimated. After: Actual.
Before: 700 participants (planned). After: 664 participants (actual).
Before: Estimated. After: Actual.
Before: Jul 2017. After: 17 Nov 2016.
Before: Recruiting. After: Completed.
NCT05206370 · Achieve Life Sciences
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Proportion of Participants With Smoking Abstinence During the Last 4 Weeks of 6 Weeks Cytisinicline Treatment Versus Placebo Treatment (Wk 3-6) Measure: Proportion of Participants With Smoking Abstinence During the Last 4 Weeks of 12 Weeks Cytisinicline Treatment Versus Placebo Treatment (Wk 9-12). After: Measure: Percentage of Participants With Smoking Abstinence From Weeks 3 to Week 6 Measure: Percentage of Participants With Smoking Abstinence From Weeks 9 to Week 12.
NCT05431387 · Achieve Life Sciences
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Proportion of Participants With Vaping Abstinence During Weeks 9 to 12. After: Measure: Percentage of Participants With Vaping Abstinence From Week 9 to 12.
NCT06435221 · Achieve Life Sciences
Before: Estimated. After: Actual.
Before: 650 participants (planned). After: 479 participants (actual).
Before: Estimated. After: Actual.
Before: 31 Dec 2025. After: 29 Sep 2025.
Before: Active not recruiting. After: Completed.